Oral mucositisEvidence-based medicineOral mucositis is a common, painful side effect of cancer treatment—be it locoregional (e.g. irradiation) or systemic (e. g. chemotherapy). Phytotherapy is often used by patients to alleviate...doi:10.1007/s00432-020-03124-xJudith Buentzel...
How Light Therapy Can Help With Oral Mucositis Managementdoi:10.1097/01.COT.0000603932.87357.aeSarah DiGiulioOvid Technologies (Wolters Kluwer Health)Oncology Times
Dental caries, a highly prevalent oral disease, impacts a significant portion of the global population. Conventional approaches that indiscriminately eradicate microbes disrupt the natural equilibrium of the oral microbiota. In contrast, biointervention strategies aim to restore this balance by introducing b...
immune systems into the biofilm matrix44. Chlorhexidine, a commonly used antimicrobial agent in oral care, has limited penetration into deep biofilm layers due to its positive charge, whereas “the fuel” (sucrose), lacking charge, can easily diffuse, facilitated by the negative charge of EPS45....
If women do take post-menopausal hormones, it should be for the shortest time possible. One of the important thing is to know about your family history. Women with a family history of cancer should take some extra care. You might be at the risk of having breast cancer if your mother ...
however further research is implicated to define its efficacy in this cohort [64,65]. Photobiomodulation (PBM) therapy has evoked interest in the treatment of acute oral mucositis following radiation therapy in head and neck oncology patients. The WALT position paper 2022 also reviewed its applicat...
In our practice, we do not recommend treatment initiation for asymptomatic patients with advanced, low-burden iNHL because of the lack of survival benefit, because 20–30% of patients will not meet treatment criteria for at least 10 years, and the median time to treatment in newly diagnosed pa...
60 mg/kg/day for five days (from day 1 to day 5), resulted in the induction of CIM.see moreA 30-minute pre-treatment oral dose of BJO and LO preceded the 5-FU regimen daily for a period of seven days, beginning on the first day and concluding on the seventh day. To ascertain ...
The most distinguishing features of TA-GVHD relatives to HCT-GVHD is pancytopenia and marrow aplasia caused by donor T cell attack [1]. Pancytopenia causes symptoms of anemia (pallor and fatigue), thrombocytopenia (easy bruising, petechia, bleeding), and leukopenia (mucositis, severe infection) ...
reduced because of, on one side, the oral mucositis that many patients develop and, on the other side, the prolonged post conditioning nausea. When oral intake is reduced and the body mass index decrease, total enteral/parenteral nutrition may be provided especially for children (see Chaps.10...